Rafiq Meena, Abel Gary, Renzi Cristina, Lyratzopoulos Georgios
Epidemiology of Cancer Healthcare & Outcomes (ECHO), Department of Behavioural Science and Health, Institute of Epidemiology and Health Care, UCL, London, UK; Centre for Cancer Research and Department of General Practice, University of Melbourne, Melbourne, Australia.
University of Exeter Medical School, Exeter, UK.
Cancer Epidemiol. 2022 Dec;81:102284. doi: 10.1016/j.canep.2022.102284. Epub 2022 Nov 9.
Steroid use is associated with increased risk of Hodgkin lymphoma (HL). However, allergic symptoms commonly treated with steroids are also presenting features of HL in some patients, thereby introducing protopathic bias in estimates of aetiological associations. It is therefore important to examine steroid prescribing patterns pre-diagnosis to understand timing of associations and when healthcare use increases before cancer diagnosis to inform future epidemiological study design.
We analysed steroid prescribing in 1232 HL patients and 7392 matched controls using primary care electronic health records (Clinical Practice Research Datalink (CPRD), 1987-2016). Using Poisson regression, we calculated monthly steroid prescribing rates for the 24-months preceding HL diagnosis, identifying the inflection point when they start to increase from baseline in cases, comparing rates with synchronous controls, and stratifying by route-of-administration and allergic disease status.
46 % of HL patients had a steroid prescription in the 24-months preceding diagnosis compared to 26 % of controls (OR 2.55, 95 %CI 2.25-2.89, p < 0.001). Odds of underlying HL were greatest in patients receiving multiple steroid prescriptions, oral steroids and in patients with a new allergic disease diagnosis. Among HL patients, steroid prescribing rates increased progressively from 7-months pre-diagnosis, doubling from 52 to 111 prescriptions/1000 patients/month.
Steroid prescribing increases during periods leading up to HL diagnosis, suggesting steroid-treated symptoms may be early presenting features of HL. A diagnostic window of appreciable length exists for potential earlier HL diagnosis in some patients; this 7-month 'lag-period' pre-diagnosis should be excluded in studies examining aetiological associations between steroids and HL.
使用类固醇与霍奇金淋巴瘤(HL)风险增加相关。然而,类固醇常用于治疗的过敏症状在一些患者中也是HL的表现特征,从而在病因关联估计中引入原发病偏倚。因此,检查诊断前的类固醇处方模式对于了解关联时间以及在癌症诊断前医疗保健使用何时增加以指导未来的流行病学研究设计很重要。
我们使用初级保健电子健康记录(临床实践研究数据链(CPRD),1987 - 2016年)分析了1232例HL患者和7392例匹配对照的类固醇处方情况。使用泊松回归,我们计算了HL诊断前24个月的每月类固醇处方率,确定病例中处方率从基线开始增加的拐点,将这些比率与同期对照进行比较,并按给药途径和过敏性疾病状态进行分层。
46%的HL患者在诊断前24个月有类固醇处方,而对照组为26%(比值比2.55,95%置信区间2.25 - 2.89,p < 0.001)。接受多次类固醇处方、口服类固醇的患者以及新诊断为过敏性疾病的患者患潜在HL的几率最高。在HL患者中,类固醇处方率从诊断前7个月开始逐渐增加,从52张/1000患者/月翻倍至111张/1000患者/月。
在HL诊断前的时期类固醇处方增加,表明类固醇治疗的症状可能是HL的早期表现特征。在一些患者中存在相当长的潜在早期HL诊断的诊断窗口;在研究类固醇与HL之间的病因关联时,应排除这7个月的诊断前“滞后期”。